register free | resend password

Pressemitteilungen zu dem Thema pharmaceuticals


Unterkategorien

PresseMitteilungen zu dem Schlagwort pharmaceuticals


NEW! LogTag® USB Data Logger Series!

The growing LogTag effective and reliable models with integrated USB port. The two LogTag They are complemented by the reusable USB loggers UTRIX-16 and UTRID-16. These two data loggers are ideal for all applications where a logger can easily be recovered and reused several times. All USB models can be plugged directly into a PC In addition, the UTRID-16 also impresses with its six level multi-alarm display. LogTag data loggers are praised worldwide for their reliability and ease of use, exce ...


30.01.2018

Pivot Pharma Licenses Thrudermic Transdermal Nanotechnology and Expands Scientific Advisory Board

VANCOUVER, BC -- (Marketwired) -- 11/09/17 -- . (OTCQB: PVOTF) ("Pivot" or the "Company") is pleased to announce the signing of a Binding Letter of Intent with Thrudermic, LLC, a privately held North Carolina company, to acquire worldwide rights to Thrudermic''s Transdermal Nanotechnology for the development and commercialization of topical cannabinoids. In addition, Dr. Joseph Borovsky and Dr. Leonid Lurya, Thrudermic''s Chief Executive Officer and Chief ...


09.11.2017

Vitality Biopharma Completes Pivotal GMP Manufacturing Agreements for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 11/01/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced completion of pivotal manufacturing agreements that enable the production of clinical-grade cannabinoid pharmaceuticals at its R&D facili ...


01.11.2017

Sermonix Pharmaceuticals Announces Recent Closure of $4.2 Million Seed Preferred Equity Bridge to Fund Operations, Prepare for Phase II Breast Cancer Study

COLUMBUS, OH -- (Marketwired) -- 10/31/17 -- Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced its recent completion of a $4.2 million Seed Preferred Equity Bridge financing round to fund ongoing operations and prepare for entry of investigational drug lasofoxifene into a Phase II clinical trial in Estrogen Receptor Positive (ER+) Metastatic Breast Cancer.Lasofoxifene, a new ...


31.10.2017

Hemogenyx Pharmaceuticals Plc ("Hemogenyx" or the "Company"): LakePharma appointed as Service Provider for lead drug development

LONDON, UNITED KINGDOM -- (Marketwired) -- 10/30/17 -- Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announced today it has chosen LakePharma, Inc. as its service provider for the development and manufacturing of Hemogenyx''s lead product, CDX bi-specific antibodies. The company believes that CDX bi-specific antibodies could replace tradi ...


30.10.2017

Easton Pharmaceuticals Announces Final Payment Completing $1.3 Million JV Agreement With Alliance Group For a 50% Property Ownership Interest and Various Businesses Including The Cultivation of Medical / Recreational Marijuana For National Canadian Market

TORONTO, ON -- (Marketwired) -- 10/20/17 -- Easton Pharmaceuticals, Inc. (OTC: EAPH) is pleased to announce its final payment which completes its $1.3 Million CDN JV agreement with Canadian based 1124123 Ontario Limited (o/a - Alliance Group) towards a 50% property ownership interest and various businesses including the cultivation of medical / recreational marijuana for national Canadian market.Easton has advanced its final payment, completing a total payment of $1.3 Million CDN to 1124123 Ont ...


20.10.2017

Pivot Pharma Executes Binding Letter of Intent to Acquire ACI Foods Inc.

VANCOUVER, BC -- (Marketwired) -- 10/19/17 -- . (OTCQB: PVOTF) ("Pivot" or the "Company"), an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals, today announces the execution of a Binding Letter of Intent to acquire Absorbent Concepts Inc. ("ACI Foods" or "ACI"). Based in Abbotsford, British Columbia, ACI processes, packages and distributes gluten-free, organic hemp nutrit ...


19.10.2017

Easton Pharmaceuticals & JV Partner Alliance Group Announces It Has Cleared Final Hurdles Toward Allowing For The Cultivation of Medical / Recreational Marijuana For National Canadian Market

TORONTO, ON -- (Marketwired) -- 10/10/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), is pleased to announce, pursuant to its previously announced closed agreement with Canadian based -- 1124123 Ontario Limited (o/a - Alliance Group) -- that its legal team has notified Easton / Alliance Group that it has cleared all exemption hurdles allowing for the Cultivation of Medical / Recreational Marijuana for the country of Canada.Easton''s JV partner, 1124123 Ontario Limited (o/a - Alli ...


10.10.2017

Canopy Growth and Skinvisible Sign Definitive Agreement to Bring New Products to Market

SMITH FALLS, ON and LAS VEGAS, NV -- (Marketwired) -- 09/28/17 -- Canopy Growth Corporation ("Canopy Growth" or the "Company") and Skinvisible Pharmaceuticals, Inc. ("Skinvisible") (OTCQB: SKVI), a research and development company with a patented drug delivery system, today announce they have signed a definitive license agreement for Skinvisible''s patented topical formulations. Per the agreement, Canopy Growth is exclusively licensed to distribute Skinvi ...


28.09.2017

Pivot Pharma and Solmic Research GmbH Sign License and Collaboration Agreement for Improved Oral Formulations of Cannabinoids

VANCOUVER, BC -- (Marketwired) -- 09/25/17 -- . (OTCQB: PVOTF) (Pivot or the Company) and its medical cannabis product division, Pivot Green Stream Health Solutions, today announce the signing of a Definitive Agreement with Solmic Research GmbH (Germany) in which Pivot will acquire worldwide rights to Solmic Solubilisation Technology for the development and commercialization of cannabinoid-containing natural extracts. Solmic''s proprietary technology provides significantly higher bioa ...


25.09.2017

Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received Regulatory Approvals For Products VS-Sense and AL-Sense For Central America and The Caribbean

TORONTO, ON -- (Marketwired) -- 09/12/17 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) and its JV partner BMV Medica SA de CV announces that its distributor Windsor Pharmaceuticals SA has received regulatory approval for two of its exclusively licensed Women''s Health Care products for Central America and the Caribbean.After filing the regulatory documents subsequent to a signed sub-licensing agreement with Panama-based Windsor Pharmaceuticals, Easton and BMV Medica have received co ...


12.09.2017

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

GLEN ROCK, NJ -- (Marketwired) -- 09/08/17 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company''s Chief Executive Officer and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the ...


08.09.2017

Circassia Announces Duaklir(R) Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease

OXFORD, UNITED KINGDOM -- (Marketwired) -- 09/07/17 -- Circassia Pharmaceuticals Plc (LSE: CIR)(LSE: CIR)Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces positive top-line results from the AMPLIFY phase III study of Duaklir®* in chronic obstructive pulmonary disease (COPD), which was conducted by the Company''s partner AstraZeneca. Duaklir® is a fixed-dose comb ...


07.09.2017

Easton Pharmaceuticals Announces $1,000,000 cdn In Payments Toward Alliance Group JV / Partnership Agreement; Announces $8,000,000 cdn Aggregate LOI Contract

TORONTO, ON -- (Marketwired) -- 09/05/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), is pleased to announce, pursuant to its previously announced Closing Agreement with Canadian based 124123 Ontario Inc. (O/A - Alliance Group), Easton has advanced $1,000,000 cdn in payments to Alliance Group. Alliance executes $8,000,000 cdn aggregate LOI contract on its 90 acres of zoned industrial land.Easton Pharmaceuticals has thus far paid $1,000,000 cdn in cash out of $1.3 million cdn to Toronto bas ...


05.09.2017

RespireRx Pharmaceuticals Inc. Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update

GLEN ROCK, NJ -- (Marketwired) -- 08/25/17 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for the treatment of neurologically controlled respiratory disorders, including obstructive sleep apnea and opioid induced respiratory depression (a form of central apnea) and other respiratory and neurological conditions, has filed its June 30, 2017 Quarterly Report on Form 10-Q and is hereby providing an update ...


25.08.2017

Easton Pharmaceuticals and Alliance Group Announces the Closing Of Its First Aggregate Contract Valued At $6,000,000 CDN On Its 90 Acre Portion Of Industrial Zoned Land

TORONTO, ON -- (Marketwired) -- 08/23/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), is pleased to announce, pursuant to its previously announced Closing with Canadian based, joint venture partner, 1124123 Ontario Limited (dba / operating as - Alliance Group) -- executes $6,000,000 CDN aggregate contract on its 90 acres of industrial zoned land.The contract Alliance Group has executed is for its Aggregate business on its 90 acres of industrial zoned land, which includes recycling, manufac ...


23.08.2017

Easton Pharmaceuticals Announces Advancing $575,000 Payment Towards Closed Agreement With Alliance Group For The Cultivation Of Medical / Recreational Marijuana For Canada and Other Revenue Producing Businesses

TORONTO, ON -- (Marketwired) -- 08/16/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), pursuant to its previously announced closing agreement with Canadian based -- Alliance Group -- Easton has advanced $575,000 towards its acquired interest in 45 acres of a 135-acre fully owned parcel of land for the cultivation, production and sale of medical / recreational marijuana to the cannabis industry and towards other revenue producing businesses.Pursuant to the agreement, Easton Pharmaceuticals h ...


16.08.2017

Fennec Provides Corporate Update and Announces Second Quarter 2017 Results

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 08/11/17 -- Fennec Pharmaceuticals Inc. (TSX: FRX) (OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the second quarter ended June 30, 2017."As we look forward to the second half of 2017, the pending SIOPEL 6 results have the potential to mar ...


11.08.2017

Easton Pharmaceuticals Announces Finalized Sub-Distribution Agreement With Gedeon Richter S.A.P.I de C.V. For Product Launch Of AmnioSense (AL-Sense)

TORONTO, ON -- (Marketwired) -- 08/10/17 -- Easton Pharmaceuticals Inc. (OTC: EAPH) Announces execution and closing of sub-distribution agreement with Gedeon Richter Plc and its Mexican subsidiary company Gedeon Richter S.A.P.I de C.V. for the product "AmnioSense."The "AmnioSense" distribution agreement represents the second product launch with Gedeon Richter S.A.P.I. de CV following the successful launch of "Gynofit" in the second quarter of this year. An initial ...


10.08.2017

AssistRx Appoints Executive Vice President of Commerical Operations

ORLANDO, FL -- (Marketwired) -- 08/08/17 -- (ARx), the leading enterprise software platform focused on specialty and highly managed medications, today named Jason Reynolds as its executive vice president of commercial operations. In this role, Reynolds will leverage his strategic vision and process expertise to accelerate the company''s misson. The iAssist platform is focused on providing specialty pharmaceutical brands superior capabilities and insights to advance the patient journe ...


08.08.2017

Mega Pharma expands rapidly in Latin America

LONDON, ENGLAND -- (Marketwired) -- 07/26/17 -- Over the last decade or so, the pharmaceutical industry has rapidly evolved, coinciding with huge changes to the global economy and the landscape of disease.One of the largest issues organisations now deal with is the world''s rising ageing population. Whereas medicine once dealt with acute disease, it has since moved focus, concentrating instead on chronic afflictions, such as diabetes.Regulations around drug development, however, and t ...


26.07.2017

Easton Pharmaceuticals Provides Shareholder Update On Acquisitions, Its Recent MMJ Initiative And Progress On Its Woman''s Diagnostics and Treatment Segment

TORONTO, ON -- (Marketwired) -- 07/24/17 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) provides shareholder update on new and existing acquisitions including its medical marijuana venture and progress on its woman''s diagnostics and treatment segment products.Easton has closed on its agreement with Alliance Group and has acquired 45 acres of agriculturally zoned land north of Toronto to cultivate, produce and facilitate the sale of its production of medical marijuana on a co-managed ...


24.07.2017

Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson''s Disease

BEVERLY HILLS, CA -- (Marketwired) -- 07/18/17 -- . (OTC PINK: RCHA), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, today announced that it has signed a support and collaboration agreement to assist Mega Bridge. Inc., a company which is to be renamed HypGen, Inc., for $100,000 and shares of HypGen common stock."HypGen is commencing work on treatments for Parkinson''s disease. Certain of the data Rich Pharmaceuticals has am ...


18.07.2017

Skinvisible Improves the Delivery of Cannabis with Patented Invisicare Technology

LAS VEGAS, NV -- (Marketwired) -- 07/07/17 -- Skinvisible Pharmaceuticals, Inc., (OTCQB: SKVI), is a topical and transdermal product development company with a proprietary drug delivery system Invisicare® which improves how ingredients are delivered to and through the skin including the medicinal components of marijuana; specifically CBD (cannabidiol) and the psychoactive marijuana ingredient THC (tetrahydrocannabinol). As part of the Company''s overall growth strategy in this market, ...


07.07.2017

Supreme Receives Sales Approval

TORONTO, ONTARIO -- (Marketwired) -- 06/28/17 -- Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (TSX VENTURE: FIRE) is pleased to announce that its wholly-owned operating subsidiary, 7ACRES, has been granted its permission to sell under the Access to Cannabis for Medical Purposes Regulations.About SupremeSupreme is a Canadian publicly traded company committed to becoming a leading cultivator and distributor of sun grown cannabis through its wholly-owned subsidiar ...


28.06.2017

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 06/28/17 -- Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated May 19, 2017 (the "Circular") for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 27, 2017. Detailed results of the vote for the election of di ...


28.06.2017

Easton Pharmaceuticals Announces It Has Received $400,000 USD In Product Purchase Orders For The Current Quarter From Its Woman''s Diagnostic And Treatment Products Business For The Mexico Market

TORONTO, ON -- (Marketwired) -- 06/26/17 -- Easton Pharmaceuticals, Inc. (OTC: EAPH), is pleased to announce it has received an approximate total of $400,000 USD in purchase orders for the quarter from its sub-distributors for the Mexican market.The purchase orders include a new order received just last week, including an upfront cash deposit which has brought the total for all Easton / BMV''s woman''s diagnostic and treatment products to approximately $400,000 USD in purcha ...


26.06.2017

Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials

BEVERLY HILLS, CA -- (Marketwired) -- 06/21/17 -- Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology announced today its principal doctor, Dr. Tontanai Numbenjapon, will commence clinical trials in Phramongkutklao Hospital in Thailand.Dr. Numbenjapon specializes in medical oncology, hematology, and stem cell transplantation. He has over 14 years of exper ...


21.06.2017

Supreme Provides License Update

TORONTO, ONTARIO -- (Marketwired) -- 06/19/17 -- Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (TSX VENTURE: FIRE) is pleased to announce that the Company''s wholly-owned subsidiary, 8528934 Canada Ltd. d/b/a 7 Acres ("7ACRES"), received several updates from Health Canada with respect to its cultivation license (the "License") pursuant to the Access to Cannabis for Medical Purposes Regulations ("ACMPR").Update on Sales Appr ...


19.06.2017

Protect Pharmaceuticals Corporation Changes Business Model

MIAMI, FL -- (Marketwired) -- 06/16/17 -- Protect Pharmaceuticals Corporation (OTC: PRTT), a Nevada Corporation, officially announces that it intends to change its name to StartCapital Corporation and modify its business model to a finance company specializing in non equity financing for start-up companies.Protect Pharmaceutical intends to change its name, business model, and stock symbol. Following shareholder approval, the new name will be StartCapital and, in conjunction with the new name, m ...


17.06.2017

Protect Pharmaceuticals Corporation Changes Business Model

MIAMI, FL -- (Marketwired) -- 06/16/17 -- Protect Pharmaceuticals Corporation (OTC: PRTT), a Nevada Corporation, officially announces that it intends to change its name to StartCapital Corporation and modify its business model to a finance company specializing in non equity financing for start-up companies.Protect Pharmaceutical intends to change its name, business model, and stock symbol. Following shareholder approval, the new name will be StartCapital and, in conjunction with the new name, m ...


17.06.2017

VANC Responds to Baseless Letter and Defamatory Comments by Mo Aziz and Canagen

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/15/17 -- Vanc Pharmaceuticals, Inc. ("Vanc") (TSX VENTURE: VANC)(OTCQB: NUVPF) responded today to a demand letter from Canagen Pharmaceuticals Inc. ("Canagen"), in which Canagen claims compensation from Vanc of $510,000. Vanc believes that the claims are wholly without merit, and intends to vigorously defend its position if an action is commenced. Vanc is issuing this news release only because Canagen took the extraordinary ...


15.06.2017

Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE(R) in Canada for Opioid Drug Dependence

PRINCETON, NEW JERSEY and MONTREAL, QUEBEC -- (Marketwired) -- 06/13/17 -- Braeburn Pharmaceuticals, Inc. ("Braeburn") and Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Knight''s New Drug Submission (NDS) has been accepted for review by Health Canada for PROBUPHINE® (buprenorphine subdermal implant) for the treatment of opioid drug dependence."Probuphine is a unique and innovative pro ...


13.06.2017

Easton Pharmaceuticals Announces It Has Finalized Agreement Terms With Alliance Group For Ownership Stake in Several Businesses On 45 Acres Of Agricultural Land, Which Includes The Cultivation of Medical Marijuana For National Canadian Market

TORONTO, ON -- (Marketwired) -- 06/12/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), is pleased to announce, pursuant to its previously announced Letter of Intent with Canadian based -- Alliance Group -- final Terms have been mutually agreed to on a final agreement to acquire an interest in a 45 acre fully owned parcel of land for the cultivation, production and sale of medical marijuana to the cannabis industry and other revenue generating businesses.Easton will invest up to $1.3 million ...


12.06.2017

Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 06/08/17 -- Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed a non-brokered private placement (the "Offering") of 1,900,000 common shares for gross proceeds of U ...


08.06.2017

Rich Pharmaceuticals Announces Institutional Review Board Submission

BEVERLY HILLS, CA -- (Marketwired) -- 06/08/17 -- Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology announced today that has filed its submission package to the Institutional Review Board (IRB) of Phramongkutklao Hospital in Bangkok, Thailand.The submission is part of a process that leads to a study for the treatment of Acute Myelocytic Leukemia (AML) i ...


08.06.2017

Supreme Announces Listing of Common Shares on the TSX.V under the symbol "FIRE"

TORONTO, ONTARIO -- (Marketwired) -- 06/01/17 -- Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (CSE: SL)(CSE: SL.CN)(CNSX: SL)(OTC PINK: SPRWF) is pleased to announce that it has received final approval from the TSX Venture Exchange ("TSX.V") to list the Company''s common shares on the TSX.V. The common shares are expected to begin trading on the TSX.V at the opening of markets on June 6, 2017 under the symbol "FIRE". In connection ...


01.06.2017

VANC Pharmaceuticals Achieves Listing of 17 Generic Products with National Distributor

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/01/17 -- VANC Pharmaceuticals Inc. (TSX VENTURE: VANC)(OTCQB: NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets announces today that 11 of the Company''s generic molecules have been listed with the major national distributor and wholesaler of drugs in Canada."I am very pleased to announce that the company has achi ...


01.06.2017

Rich Pharmaceuticals Announces Clinical Site in Thailand

BEVERLY HILLS, CA -- (Marketwired) -- 05/31/17 -- Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology announced today that it has selected a site and obtained investigator''s interest at Phramongkutklao Hospital in Bangkok, Thailand. Rich has engaged CMIC ASIA-PACIFIC, PTE. LTD. ("CMIC") to assist in this project and they have already ...


31.05.2017

Mark Paul appointed President of CROS NT LLC

CHAPEL HILL, NC -- (Marketwired) -- 05/30/17 -- CROS NT announced today that Mark Paul has been appointed President of the company''s North American operations effective June 1, 2017. Paul brings a wealth of operational and commercial experience to the role and most recently has been serving as Senior Vice President of Program Management for CROS NT."Mark is the perfect candidate for what is an important role within the business. He has a strong customer focus and a great underst ...


30.05.2017

Fennec Announces Launch of European Named Patient Programme for Sodium Thiosulfate for Pediatric Patients With Standard Risk Hepatoblastoma

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 05/30/17 -- Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced the launch of a Named Patient Programme (NPP) in Europe for STS. Fennec''s NPP is intended to make STS available to patients before commercial availability in certain countries. Where ...


30.05.2017

UPDATE - CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC -- (Marketwired) -- 05/24/17 -- CROS NT today announced the go-live of its RaveX team in an extension of the company''s partnership with .Under the partnership, CROS NT will offer its customers -- the latest generation of Medidata''s industry-leading EDC system, Medidata Rave-- as well as Medidata''s randomization and trial supply management (RTSM) system, . The Data Management division in CROS NT offers Sponsors of c ...


24.05.2017

Easton Pharmaceuticals Announces It Has Signed an LOI to Acquire An Interest in a 45 Acre Parcel for the Cultivation of Medical Marijuana in Toronto, Canada; Wholly Owned Subsidiary, iBliss in Birmingham''s UK Vaper Expo

TORONTO, ON -- (Marketwired) -- 05/24/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce that it has signed a Letter of Intent with Canadian Alliance Group to acquire an interest in their 45 acre fully owned parcel of land for the cultivation, production and sale of medical marijuana to the cannabis industry. Easton''s wholly owned subsidiary, iBliss Inc. is currently in Birmingham, UK for this weekend''s Vaper expo.Easton has entered into an LOI agre ...


24.05.2017

CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC -- (Marketwired) -- 05/23/17 -- CROS NT today announced the go-live of its RaveX team in an extension of the company''s partnership with .Under the partnership, CROS NT will offer its customers -- the latest generation of Medidata''s industry-leading EDC system, Medidata Rave-- as well as Medidata''s randomization and trial supply management (RTSM) system, . The Data Management division in CROS NT offers Sponsors of c ...


23.05.2017

VANC Pharmaceuticals Announces Canadian Distribution Agreement for INSTI® HIV-1/HIV-2 Antibody Test

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/17/17 -- VANC Pharmaceuticals Inc. (TSX VENTURE: VANC)(OTCQB: NUVPD) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, announces today it has entered into a Canada-wide distribution agreement for INSTI® HIV-1/HIV-2 Antibody Test (INSTI)."We are very pleased to have acquired the Canadian distribution rights to INSTI," comment ...


17.05.2017

Fennec Provides Corporate Update and Announces First Quarter 2017 Results

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 05/12/17 -- Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the first quarter ended March 31, 2017.Upcoming Events for 2017Investor Events:Corporate Milestones:"Our highest priority remains the preparat ...


12.05.2017

Supreme Updates Board of Directors and Provides Licensing Update

TORONTO, ONTARIO -- (Marketwired) -- 05/08/17 -- Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (CSE: SL)(CSE: SL.CN)(CNSX: SL) is pleased to announce that Mr. Ron Factor, B.A.Sc, MBA, has joined its Board of Directors. Mr. Factor was the founder of the global supply chain management consulting practice at Deloitte Consulting in Toronto. He will replace Mr. Chuck Rifici on the Board, who has resigned to focus his efforts on a new venture. The Supreme Board of Dir ...


08.05.2017

Easton Pharmaceuticals Announces Signing LOI For The Acquisition Of Revenue Producing, Israel Based Therapeutics Company, Herbs Of Kedem

TORONTO, ON -- (Marketwired) -- 05/02/17 -- Easton Pharmaceuticals, Inc. (OTC: EAPH) announces it has signed an LOI for the acquisition of revenue producing, Israel based therapeutics company, Herbs of Kedem.Herbs of Kedem is an Israeli based company with sales in excess of $2,200,000 US and healthy profit margins with a current net profit of approximately $1,500,000 US with minimal marketing exposure. Herbs of Kedem currently has a total of 10 adult skin care and anti-aging products, 5 hair ca ...


02.05.2017

Fennec to Present at Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 04/27/17 -- Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the PIONEERS 2017 Joseph Gunnar Conference on Tuesday, May 2 at 2:00 PM ET in the South Salon II at the Mandarin Oriental Hotel in New York City. Management will also be available to meet with investors during the conference.The Fennec presentation slides can be accessed by visiting the investor sec ...


27.04.2017

Easton Pharmaceuticals Announces Signing NDA and Starts Negotiations For Acquisition

TORONTO, ON -- (Marketwired) -- 04/24/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce that it has signed a non-disclosure / confidentiality agreement with a Producer of Crop Protection, Fertilizer and Plant Wash Products Company based in Israel.Easton has signed non-disclosure agreement and has started negotiations with a high level meeting planned with the Israeli based company this week to discuss possible acquisition / joint venture / distribution agreements betwee ...


24.04.2017

VANC Pharmaceuticals Appointment of Mr. Alan Arnstein to its Board of Directors

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/20/17 -- VANC Pharmaceuticals Inc. (TSX VENTURE: VANC)(OTCQB: NUVPD) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets is pleased to announce the appointment of Mr. Alan Arnstein to VANC''s Board of Directors."We are delighted to have Mr. Arnstein join our company and believe it is a vote of confidence on our long term s ...


20.04.2017

Easton Pharmaceuticals Announces Signing Of Purchase Agreement Completing The Acquisition Of Revenue Producing Vaporizer and e-Liquids Manufacturer iBliss, Inc.

TORONTO, ON -- (Marketwired) -- 04/20/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce the execution of final agreement completing the 100% acquisition of revenue generating vaporizer and e-liquids manufacturer, iBliss Inc. and its holding company.Easton Pharmaceuticals and iBliss, Inc. executed the closing final agreement, officially concluding the 100% acquisition of iBliss from its holding company. Terms of the acquisition included installment cash payments to be pa ...


20.04.2017

Bradmer Announces Fourth Quarter and Full Year 2016 Financial Results

TORONTO, ONTARIO -- (Marketwired) -- 04/18/17 -- Bradmer Pharmaceuticals Inc. (NEX: BMR.H) ("Bradmer" or the "Company") today announced its fourth quarter and full year 2016 financial results.Financial ResultsAmounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").For the three months ended December 31, 2016, the Company recorded a net loss of $21,000 or $0.001 per common share ...


18.04.2017

Groupe Athena, Inc. Posts Strong 3rd Quarter Results

MUMBAI, INDIA -- (Marketwired) -- 04/11/17 -- Groupe Athena, Inc. (OTC: GATA) announced today revenues of $10,665,210 for the period ending March 31, 2016. Operating income before depreciation, amortization and taxes were $1,662,277 while net income was $1,233,147.Total revenues for the 9 month period this fiscal year were $43,816,222 which is well on pace to meet the previously announced 12 month guidance. Cash reserves in the form of short term investments and deposits are extremely healthy w ...


11.04.2017

Easton Pharmaceuticals Announces Finalization Of Agreement For The Acquisition Of Major Vaporizer and e-Liquids Manufacturer iBliss Inc; Annual Sales Projected To Once Again Reach $15,000,000 With Healthy Profit Margins in Excess of 40%

TORONTO, ON -- (Marketwired) -- 04/11/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces it has finalized all terms of the Acquisition Agreement to acquire revenue producing vaporizer, e-liquids manufacturer iBliss Inc., of Toronto, Ontario, whereas legal counsel will be quickly concluding the closing of the transaction.After various delays and much negotiation, Easton Pharmaceuticals is pleased to announce that both Easton and iBliss have agreed to and finalized all terms of the Acq ...


11.04.2017

Supreme Announces Conditional Approval to List on the TSX.V

TORONTO, ONTARIO -- (Marketwired) -- 04/10/17 -- Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (CSE: SL)(CSE: SL.CN) is pleased to announce that it has received conditional approval from the TSX Venture Exchange ("TSX.V") to list the Company''s common shares on the TSX.V.John Fowler, President and CEO, stated: "Graduating from the CSE to the TSX.V is an important milestone for Supreme. We enjoyed tremendous success throughout our time on ...


10.04.2017

Fennec Provides Corporate Update and Announces Fiscal Year Ended December 31, 2016 Financial Results

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 03/30/17 -- Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2016."We are pleased with the progress made throughout 2016 including our $5.0 million equity financing and additi ...


30.03.2017

VANC Pharmaceuticals Provides Marketing Update

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 03/24/17 -- VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE: VANC)(OTCQB: NUVPD), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets provides marketing update as part of its ongoing program to bring value added products to the Canadian pharmacy industry."I am pleased to announce that VANC''s premium natural iron supplement Hema-Fer™ h ...


24.03.2017

Easton Pharmaceuticals Announces Advancing $300,000 Payment To CommonSense Ltd. Paving The Way For The Anticipated Closing Of Exclusive Sub-Distribution Agreement For Product AL-Sense with 2nd Quarter Launch

TORONTO, ON -- (Marketwired) -- 03/22/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces it has forwarded together with BMV Medica a $300,000 payment to CommonSense of Israel clearing the way for the closing of an anticipated exclusive sub-distribution agreement with a major, multi-national, pharmaceutical company for the women''s diagnostic product AL-Sense (AmnioSense). In addition, Easton / BMV through their commercial alliance partner Ackerman Pharma, provides update on ...


22.03.2017

Rich Pharmaceuticals to Launch CannCodex, marking its entry into Medicinal Cannabis Industry

BEVERLY HILLS, CA -- (Marketwired) -- 03/21/17 -- Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today that it has reached agreement with I Tech Health Corp. to form a subsidiary and launch CannCodex to serve the Medicinal Cannabis industry as well as provide data and services to pharmaceutical companies worldwide.The strategic move was id ...


21.03.2017

Easton Pharmaceuticals Provides Update On Its Previous Investment Into AMFIL Technologies and Their Recent Revenue Producing Acquisitions & The GROzone Technology For The Medical Marijuana Industry; Initiates Negotiations For Proposed Investment

TORONTO, ON -- (Marketwired) -- 03/15/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) Provides update on its previous investment into AMFIL Technologies and their recent revenue generating business acquisitions and their AMFIL GROzone technology for the medical marijuana industry (OTC PINK: AMFE).Easton Pharmaceuticals in 2014 completed an investment into AMFIL Technologies with an option to purchase additional equity. The investment was originally used to assist AMFIL in general expenses a ...


15.03.2017

Supreme Announces License Update

TORONTO, ONTARIO -- (Marketwired) -- 03/10/17 -- Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (CSE: SL)(CSE: SL.CN) announces that its wholly-owned subsidiary 7 ACRES has received a renewal of its license to cultivate cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations ("ACMPR"). Supreme also understands that Health Canada is in the final phase of its review of 7 ACRES'' application (the "Application") for ...


11.03.2017

Easton Pharmaceuticals Provides Update On Acquiring Major Vaporizer and e-Liquids Manufacturer iBliss, Inc.

TORONTO, ON -- (Marketwired) -- 03/08/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) provides an update on its acquisition of revenue producing vaporizer, e-liquids manufacturer and medical marijuana company, iBliss Inc., of Toronto, Ontario, Canada.Since the previously announced letter of intent to acquire revenue generating vaporizer manufacturer and medical marijuana company iBliss Inc., both parties have engaged in detailed negotiations to reach terms on a final closing agreement. Nego ...


08.03.2017

Easton Pharmaceuticals Announces The Closing Of A Financing Facility With Additional Financing Commitments; Provides Other Updates

TORONTO, ON -- (Marketwired) -- 03/03/17 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Announces it has closed on an interim financing with additional financing funds committedEaston Pharmaceuticals has closed on an interim financing facility up to $2,000,000, of which it has been provided access to. This facility also provides for an additional commitment of funds depending upon the company''s requirements. Terms of the facility are in the form of a loan, convertible to restricted ...


03.03.2017

Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Expanding From U.S., Japan

COLUMBUS, OH -- (Marketwired) -- 02/28/17 -- Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced it licensed worldwide rights to develop and commercialize oral lasofoxifene, its lead investigational drug, from Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Sermonix initially licensed oral lasofoxifene rights from Ligand in February 2015, covering the U.S., Japan and other select ...


28.02.2017

VANC Pharmaceuticals Launches New OTC Laxative Product Sennace

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 02/27/17 -- VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE: VANC)(OTCQB: NUVPD), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets announces the launch of a new OTC laxative to the market place. Sennace represents another in a series of OTC products launched and to be launched by VANC."We are very excited about our new laxative offering," ...


27.02.2017

RespireRx Pharmaceuticals Inc. to Present at BIO CEO & Investor Conference 2017

GLEN ROCK, NJ -- (Marketwired) -- 02/10/17 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for the treatment of respiratory disorders for which there are no approved pharmaceuticals, particularly sleep apneas and respiratory depression resulting from pain management medicines and disabilities such as spinal cord injury, announces that the Company''s President, Chief Executive Officer and Vice ...


10.02.2017

Fennec to Present at 19th Annual BIO CEO & Investor Conference

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 02/09/17 -- Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the 19th BIO CEO & Investor Conference on Monday, February 13, 2017 at 1:30 PM ET at the Waldorf Astoria Hotel in New York City.The Fennec presentation will be webcast live and can be accessed at or by visiting the investor section of the Company''s website at . A replay of the presentation ...


09.02.2017

Easton Pharmaceuticals Provides Update On its Licensed Women''s Diagnostics Products (VS-Sense, AL-Sense) and Other Updates

TORONTO, ON -- (Marketwired) -- 02/08/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) provides contract negotiation update on the company''s licensed women''s diagnostics products (VS-Sense, AL-Sense) and update on its investment in AMFIL.Easton has been in negotiations for both its licensed AL-Sense and VS-Sense women''s diagnostic products which are now considered final late stage negotiations. On Wednesday, February 8th, both BMV Medica and Easton Pharmaceut ...


08.02.2017

VANC Pharmaceuticals Provides Corporate Update

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 02/07/17 -- VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE: VANC)(OTCQB: NUVPD), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets announces the Company has hired two directors of sales for both eastern Canada and western Canada."I am pleased to announce the successful recruitment of two pharmaceutical sales experts, Devin Jensen and Rick Sto ...


07.02.2017

Easton Pharmaceuticals and BMV Medica Announces First Shipment of Gynofit To Multi-National Pharmaceutical Company, Gedeon Richter, Towards Its Purchase Order, Has Been Received For February 16th Product Launch in Puerto Vallarta, Mexico

TORONTO, ON -- (Marketwired) -- 02/03/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces after having received initial payment towards product purchase order from pharmaceutical multi-national Gedeon Richter''s Plc subsidiary - Gedeon Richter Mexico S.A.P.I. de C.V., the first shipment of "Gynofit" bacterial vaginosis treatment has been shipped and received in Mexico in preparation of its product launch in Puerto Vallarta, Mexico for February 16th.Gedeon Richter w ...


03.02.2017

VANC Pharmaceuticals Provides Corporate Update

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 01/31/17 -- VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE: VANC)(OTCQB: NUVPD), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, provides the following update from Bob Rai, Interim CEO of VANC:As we begin 2017, I am proud to say that the Company is now seeing the fruits of some very hard work, critical strategic decisions and now traction towar ...


31.01.2017

VANC Pharmaceuticals Announces Non Brokered Private Placement

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 01/30/17 -- VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE: VANC) (OTCQB: NUVPD), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce a non-brokered private placement of up to 5,416,666 units of the Company at a price of $0.24 per unit (the "Units") for gross proceeds of up to $1,300,000 (the "Offering").E ...


30.01.2017

Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome

LOS ANGELES, CA -- (Marketwired) -- 01/23/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with the newly-established Food for Health Center at the University of Nebraska ("NU") to study the role of the microbiome and RP-G28 in metabolic syndro ...


23.01.2017

Easton Pharmaceuticals Signs Letter Of Intent to Acquire Major Vaporizer and e-Liquids Manufacturer iBliss Inc.

TORONTO, ON -- (Marketwired) -- 01/23/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) Announces that it has signed a letter of intent to acquire 100% of revenue producing vaporizer manufacturer iBliss Inc., of Toronto, Ontario, Canada.iBliss Inc. is a tremendously fast growing vaporizer and e-liquids manufacturing company with surging international sales projected to conservatively reach and surpass $15,000,000 per year fairly quickly. iBliss currently generates several millions of dollars ...


23.01.2017

Biotica Pharmaceuticals Announces Board of Advisors -- Distinguished Scientists to Help Shape Biotica''s Future

SARASOTA, FL -- (Marketwired) -- 01/17/17 -- Biotica Pharmaceuticals Inc. (Biotica), a biopharmaceutical company, which engages in discovering, developing, and commercializing cannabinoid-based medicines for Neuropathic pain, Cancer, Alzheimer''s, Parkinson''s, Esophagitis, and Immune Enhancement, announces today that it has begun strengthening the company by the formation of its board of advisors. Biotica''s newly formed Board of Advisors includes scientists with ...


17.01.2017

Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors

LOS ANGELES, CA -- (Marketwired) -- 01/17/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced it has appointed William Merino, Ph.D., to its Board of Directors. Dr. Merino will occupy a newly-created seat, advising on regulatory, clinical and related strategies.Dr. Merino has over 30 years of global ex ...


17.01.2017

Easton Pharmaceuticals and Partner BMV Medica Announce Receipt of First Purchase Order For Mexico''s Launch for Gynofit -- Lactic Acid Gel Treatment From Gedeon Richter

TORONTO, ON -- (Marketwired) -- 01/04/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), along with its partners BMV Medica and its host Ackerman Pharma, announce receipt of initial purchase order for the Gynofit Lactic Acid Gel Treatment from Gedeon Richter for their product launch in Mexico slated for this February.As per its recently announced distribution agreement with Gedeon Richter, Easton / BMV and their host laboratory, Ackerman Pharma, have received an initial purchase order for the ...


04.01.2017

Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences

LOS ANGELES, CA -- (Marketwired) -- 01/03/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that clinical microbiome data from its Phase 2a clinical trial of RP-G28 in patients with lactose intolerance were published in the Proceedings of the National Academy of Science ("PNAS-Plus") PNAS 2 ...


03.01.2017

Supreme Announces Voting Results for the Annual General Meeting of Shareholders

TORONTO, ONTARIO -- (Marketwired) -- 12/16/16 -- Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (CSE: SL)(CSE: SL.CN) announces that at the annual general meeting of its shareholders (the "Meeting") held in Toronto, Ontario on December 16, 2016, the shareholders approved the election of Mr. Chuck Rifici as a director of the Company. Mr. Rifici joins current directors Mr. Michael La Brier, Mr. Scott Walters, Mr. Navdeep Dhaliwal and Mr. John Fowler who w ...


17.12.2016

Easton Pharmaceuticals and Partner BMV Medica Sign First Sales & Marketing Agreement with European Based, Multi-National Pharmaceutical Company, Gedeon Richter, For Women''s Health, Sales & Marketing of its Gynofit -- Lactic Acid Gel Treatment of Bacteria

TORONTO, ON -- (Marketwired) -- 12/14/16 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce that its partner BMV Medica SA de C.V. through its host company Ackerman Pharma, has signed a Sales & Marketing Agreement with Gedeon Richter Mexico S.A.P.I. de C.V. a Mexican-based company and affiliate of Gedeon Richter Plc, for Easton / BMV''s "Gynofit" Lactic Acid Gel for the treatment of Bacterial Vaginosis in Mexico.The sales and marketing agreement is f ...


14.12.2016

Supreme Pharmaceuticals Closes $55 Million Offering

TORONTO, ONTARIO -- (Marketwired) -- 12/13/16 -- Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (CSE: SL) is pleased to announce the closing of its $50 million bought deal private placement (the "Brokered Offering") and concurrent $5 million non-brokered private placement (together with the Brokered Offering, the "Offering") for aggregate gross proceeds of $55 million.Pursuant to the Offering, the Company issued a total of $55 million of 10% u ...


13.12.2016

Sermonix Pharmaceuticals Signs Exclusive Licensing Agreement to Further Explore Lasofoxifene for Breast Cancer Treatment

COLUMBUS, OH -- (Marketwired) -- 12/07/16 -- Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced that it signed a licensing agreement through which Sermonix will gain exclusive rights to Duke University intellectual property related to the use of lasofoxifene -- Sermonix''s lead investigational drug -- in the treatment of endocrine-resistant breast cancer. Duke will ...


07.12.2016

VANC Pharmaceuticals Announces Intent To Acquire HealthTab

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 12/05/16 -- VANC Pharmaceuticals Inc. (TSX VENTURE: NPH) (OTCQB: NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, announces today it has signed a non-binding term sheet to acquire all outstanding common shares of HealthTab Inc., ( "HealthTab") a proven point-of-care solution provider to Canadian pharmacies.The strategic ...


05.12.2016

Fennec Announces the Lancet Oncology Publication of Children''s Oncology Group Study of Sodium Thiosulfate

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 12/01/16 -- Fennec Pharmaceuticals Inc. (TSX: FRX) (OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced The Lancet Oncology published the results from the Children''s Oncology Group, "Effects of Sodium Thiosulfate versus Observation on Development of Cisplatin-Induced Hearing Loss ...


01.12.2016

Easton Pharmaceuticals Announces Negotiations For The Filing Of A Medical Marijuana Application In Jamaica Toward Exporting Medicinal Marijuana Into various Countries Including Canada, Mexico, and Brazil

TORONTO, ON -- (Marketwired) -- 11/28/16 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces it has entered into negotiation for the purpose of filing an application in Jamaica for the purpose of growing and exporting medical concentrated Marijuana into various countries including Canada, Mexico, and Brazil.Easton Pharmaceuticals has previously demonstrated its strong desire and commitment to enter the lucrative market of medical marijuana. To further demonstrate its commitment, Easton c ...


28.11.2016

Easton Pharmaceuticals Announces Receipt of all Technical Documents from Biolyse Pharma for Filing of a Marketing Authorization Dossier Towards Fast Track Approval with the Mexican Ministry of Health for Cancer Drug Paclitaxel

TORONTO, ON -- (Marketwired) -- 11/15/16 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces that all required technical documents have been received from Biolyse Pharma Corporation of St. Catharines, Ontario, Canada, for cancer drug Paclitaxel and are now ready for submission for fast track approval with the Mexican Ministry Of Health.Easton Pharmaceuticals and partner BMV Medica have secured the rights from Biolyse Pharma to distribute the generic cancer drugs Docetaxel and Paclitaxel f ...


15.11.2016

Fennec Provides Corporate Update and Announces Third Quarter 2016 Results

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 11/14/16 -- Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the third quarter ended September 30, 2016.Corporate UpdateUpdated Interim results from ""SIOPEL 6: A multi-centre open label randomised ...


14.11.2016

Titan Pharmaceuticals Reports Third Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/09/16 -- (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, today reported financial results for the third quarter ended Sept. 30, 2016.Titan reported $26,000 in license revenue for the third quarter of 2016, compared with no revenue for the comparable quarter in 2015. License revenue in the third quarter of 2016 included r ...


09.11.2016

Easton Pharmaceuticals Announces Receipt of Preliminary Proposal From Major Multi National Pharmaceutical Company For Its Regulatory Approved, Patented, VagiSan (VS-Sense) Womens Diagnostic Test For The Countries Mexico and Ecuador

TORONTO, ON -- (Marketwired) -- 11/07/16 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) and partner BMV Medica SA have received a preliminary proposal from a major multi-national pharmaceutical company for its regulatory approved, patented VagiSan (known as VS-Sense) woman''s diagnostic test Bacterial Vaginosis for Mexico and Ecuador. Negotiations with a second major pharmaceutical company for other Easton/BMV products has moved to contract phase.The preliminary proposal comes after ...


07.11.2016

Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/16 -- (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced that it will host a live conference call at 4:15 p.m. EST / 1:15 p.m. PST on Wednesday, Nov. 9, 2016 to discuss the company''s financial results as of Sept. 30, 2016. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beeb ...


03.11.2016

Bradmer Announces Third Quarter 2016 Financial Results

TORONTO, ONTARIO -- (Marketwired) -- 11/02/16 -- Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") (NEX: BMR.H) today announced its third quarter 2016 financial results.Financial ResultsAmounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").For the three months ended September 30, 2016, we recorded a net loss of $20,000 or $0.001 per common share based on the weighted ...


02.11.2016

Easton Pharmaceuticals and Partner BMV Medica Announce Closing Of First Distribution Agreement For Three Exclusively Licensed Women''s Health Products: VagiSense, AmnioSense and Gynofit With Windsor Pharmaceuticals For Central America and The Caribbean

TORONTO, ON -- (Marketwired) -- 10/31/16 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has closed its first Sales & Distribution agreement with Windsor Pharmaceuticals SA for three of its exclusively licensed Women''s Health products for Central America and the Caribbean. Windsor Pharmaceuticals SA expects to launch in Q1, 2017, once streamlined regulatory submissions are granted, with sales growing to several million dollars by year three.The signed agreement inclu ...


31.10.2016

Fennec Announces Update of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the International Society of Paediatric Oncology (SIOP) 2016 Meeting

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 10/24/16 -- Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced the presentation of updated interim results of SIOPEL 6 at the 2016 SIOP meeting in Dublin, Ireland on October 22, 2016.Penelope Brock, M.D., PhD, International Chair of SIOPEL, presented the "T ...


24.10.2016

Popular Science Recognizes Probuphine as One of the 2016 "Best of What''s New"

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/20/16 -- (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, is very pleased that Probuphine® has been recognized as one of the "12 Most Important Innovations of the Year" in the Health category in Popular Science''s annual "Best of What''s New" issue. Probuphi ...


20.10.2016

Innovus Pharmaceuticals Supplement Androferti Improves Male Fertility, says top medical expert

SAN DIEGO, CA -- (Marketwired) -- 10/20/16 -- The ("VCRM"), one of the nation''s leading fertility centers, today recommends ®, a supplement from San Diego-based , Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company.The supplement can be used to help solve the growing issue of male infertility, says , founder and Medical Director of the (VCRM).When couples have trouble conceiving, the conventional wisdom is that the problem lies with the woman. "But ...


20.10.2016

Dr. Bassam Damaj of Innovus Pharma: Rapid Growth Plan Succeeds

SAN DIEGO CA -- (Marketwired) -- 10/11/16 -- Innovus Pharma (OTCQB: INNV) is one of those very rare microcap companies with real products, real revenues, and a proven record of rapid growth, according to a new updated analysis by CEOCFO magazine.CEOCFO states that the San Diego-based consumer and pharmaceutical company pulled in more than $1 million product sales in the second quarter of 2016, an increase of over 400% compared to the first quarter of 2016. It''s on track for more than ...


11.10.2016

Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum

LOS ANGELES, CA -- (Marketwired) -- 10/05/16 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company''s Chief Executive Officer, Michael Step, presented at the 4th Microbiome R&D Business Collaboration Forum & Panel on October 4, 2016 in San Diego, CA.Mr ...


05.10.2016

AssistRx Shares Insight Into Maximizing Workflow Efficiency at the 7th Hub and SPP Model Optimization Conference

ORLANDO, FL -- (Marketwired) -- 09/28/16 -- announces its Vice President of Strategic Development, Andrew Dunning, will present at the 7th Hub and SPP Model Optimization Conference on September 29, 2016. Mr. Dunning will share his expert insight into how specialty pharmaceutical brands can simplify access and accelerate time-to-therapy for patients by leveraging technology, such as the , to replace an archaic paper/fax based process.By utilizing technology that streamlines the prescribing proc ...


28.09.2016

AssistRx Announces Integration With Leading E-Prescribing Service, NewCrop

ORLANDO, FL -- (Marketwired) -- 09/27/16 -- , creator of the -- the leading patient-focused software solution for prescribing specialty medications -- today announces its partnership with e-prescribing service, . Through this relationship, NewCrop will have the ability to offer its clients a state-of-the-art software solution that uses technology to eliminate paper and streamline communication between prescribers, pharmacies and manufacturers, drastically reducing the time it takes for patient ...


27.09.2016



All members: 9 376
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 42


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.